[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651013":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":37,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Tempus AI","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Substudy OLV002: Pediatric Acute Myeloid Leukemia (pAML)",null,"Prospective, decentralized, participant\u002Fcaregiver-mediated data registry for real-world evidence generation in pediatric AML. This is a minimal-risk, observational registry focused on pAML- intentional data collection (i.e., surveys\u002FPROs), and associated evidence generation. Pediatric patients with confirmed AML diagnosis (eg, consented and authorized patients with completed laboratory test results and\u002For confirmed cancer diagnoses) in the United States. Pediatric subject's parent\u002Flegally authorized representative will consent for their participation and inclusion into the registry.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Olivia Study Team","CONTACT","833-514-4187","support@oliviahealth.ai",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Chicago","Illinois","60654","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-87.65005,41.85003,{"lat":30,"lon":29},[33,35],{"name":34,"role":15,"phone":16,"phoneExt":10,"email":17},"Mark Shapiro",{"name":34,"role":36,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[40],{"name":41,"class":42},"Blood Cancer United","OTHER","100651013","tempus-open-link-for-individual-voices-in-innovative-analytics-registry-platform-protocol-for-multimodal-real-world-evidence-in-cancer-100651013",false,"NCT07756034","Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer","TEMPUS ONCO-OLIVIA Registry","ONCO-OLIVIA","ONCO-OLIVIA Registry:\n\nInclusion Criteria:\n\n* Adults or children (all ages) with a pathologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) documented in the medical record; disease-specific cohorts may further define subtypes (e.g., stage, biomarker)\n* Receiving care in the United States and\u002For U.S. Territories\n* Participant (and\u002For legally authorized representative) is able and willing to provide electronic informed consent\u002Fpermission and authorization via Olivia; with re-consent at age of eighteen if applicable\n* Willing to authorize medical record retrieval under HIPAA Right of Access and\u002For TEFCA IAS\n* Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and optional surveys\n\nExclusion Criteria:\n\n* Not Applicable\n\nSubstudy OLV002: Pediatric Acute Myeloid Leukemia (pAML):\n\nInclusion Criteria:\n\n* Receiving or have received care in the United States and\u002For U.S. Territories\n* Participant (and\u002For legally authorized representative) is able and willing to provide electronic informed consent\u002Fpermission and authorization via the platform; with re-consent at age of eighteen if applicable\n* Legally authorized representative of participant who is deceased is able and willing to provide electronic informed consent\u002Fpermission and authorization via the platform\n* Willing to authorize medical record retrieval under HIPAA Right of Access and\u002For TEFCA IAS\n* Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and cohort dependent PROs\u002Fsurveys\n* Pediatric patients with a confirmed diagnosis of Acute Myeloid Leukemia (AML) including the following AML subtypes per WHO\u002FICC classification: AML with core-binding factor rearrangements (AML-CBF), AML with inv(16) (AML-NV16), acute promyelocytic leukemia (APL), AML with KMT2A rearrangement (AML-KMT2A), AML with mutated NPM1 (AML-NPM1), AML with bZIP CEBPA mutations (AML-bZIP), AML with MECOM rearrangement\n\nExclusion Criteria:\n\n\\- Suspected but unconfirmed acute myeloid leukemia",true,"ALL",{"count":54,"type":55},1000,"ESTIMATED","5 Years","OBSERVATIONAL","This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus.\n\nOlivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a retrospective and prospective registry by working with over 1,000 healthcare systems to combine electronic health records (EHR) and Patient Reported Outcomes (PROs) in a single spot.\n\nThere may be sub-studies as an add-on to this parent protocol. The sub-studies will address specific goals of the targeted research activities and will usually include additional information specific to each research study.",[60,61,62,63],"Cancer","Solid Tumor Cancer","Pediatric Acute Myeloid Leukemia","Hematologic Malignancies",[65,66,67],"Registry","Olivia","De-centralized","2026-08-04",{"date":70,"type":71},"2026-08-10","ACTUAL",{"date":73,"type":55},"2026-08",{"date":75,"type":55},"2031-07",{"name":5,"class":6},1]